US equities |
NVDA $239.80 ▲+2.50% SPCX $169.64 ▲+6.72% MU $1,060.80 ▼-1.31% TSLA $380.84 ▲+2.77% SNDK $1,693.96 ▼-1.51% MSFT $528.50 ▲+2.12% INTC $116.51 ▼-2.36% META $743.73 ▲+2.15%
FinancialContent

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

72.24 +15.76 (+27.90%)
Delayed Quote Updated: 3:18 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
What's Driving the Market Sentiment Around Vaxcyte? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
(PCVX) - Analyzing Vaxcyte's Short Interest ↗
 
Via Benzinga
News headline image
(PCVX) - Analyzing Vaxcyte's Short Interest ↗
 
Via Benzinga
News headline image
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗
Via The Motley Fool
Topics Stocks
News headline image
Are Small-Cap Stocks A Buy After Russell 2000 Correction? ↗
Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines. 
Via Benzinga
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Peering Into Vaxcyte's Recent Short Interest ↗
 
Via Benzinga
News headline image
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
News headline image
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank ↗
Via The Motley Fool
Topics Stocks
News headline image
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗
Via The Motley Fool
Topics Stocks
News headline image
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers ↗
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga
News headline image
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher ↗
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
News headline image
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market ↗
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
News headline image
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >